Market Currents
Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at...
-
Monday, June 4, 2012, 9:30 AM ETGalena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at ASCO reveals booster inoculations are well-tolerated and appear to maintain long-term peptide-specific immunity and reduce disease recurrence rates. Cantor Fitzgerald starts coverage of GALE at Buy, saying its breast cancer treatment "would represent major advances in prevention of disease."
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
